Last reviewed · How we verify
NCT06706284
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
Phase 4 trial testing Semaglutide Injectable Product in Spinal Cord Injuries in 50 participants. Currently enrolling.
1 September 2028
Quick facts
| Lead sponsor | Marzieh Salehi |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 11 April 2025 |
| Primary completion | 1 September 2028 |
| Estimated completion | 1 March 2029 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Semaglutide Injectable Product — full drug profile →
- Placebo
Conditions studied
- Spinal Cord Injuries — all drugs for Spinal Cord Injuries →
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
Sponsor
Marzieh Salehi
Who can join
Adults 18 to 70, any sex, with Spinal Cord Injuries or Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
It is not known whether a new diabetes drug, semaglutide, is an effective treatment for type 2 diabetes for persons with spinal cord injury (SCI), a population at higher risk for this condition. Therefore, this study looks at the effect of semaglutide on glucose levels in the body and other information about type 2 diabetes and obesity.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06706284
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Semaglutide Injectable Product
Trials testing the same drug.
- NCT05646199 — Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS) · Phase 2, PHASE3 · not yet recruiting
- NCT06500429 — A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) A · Phase 2 · completed
- NCT06423599 — Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure · Phase 2, PHASE3 · recruiting
- NCT05895643 — Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity? · Phase 2 · completed
- NCT05786521 — Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults · Phase 4 · completed
Other recruiting trials for Spinal Cord Injuries
Currently open trials in the same condition.
- NCT07109804 — Cuneiform Nucleus (CnF) Deep Brain Stimulation for Gait Facilitation Following Spinal Cord Injury · NA · recruiting
- NCT07472985 — Protocol for Rapid Onset of Mobilization in Patients With Traumatic Spinal Cord Injury II (PROMPT-SCI II) Trial · NA · recruiting
- NCT07210411 — Acute and Chronic Repercussion of Spinal Cord Stimulation After Spinal Cord Injury · NA · recruiting
- NCT07488793 — Remote Ischemic Conditioning for PwSCI · NA · recruiting
- NCT07536386 — Self-balancing Personal Exoskeleton for SCI (WIP) · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06706284 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Marzieh Salehi
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06706284.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing